Read on Twitter
The first fully-tested covid-19 vaccine has been authorised for use in Britain. How did the country's regulator approve the Pfizer-BioNTech jab so quickly? A bumper thread 
(1/10) https://econ.st/36v2q3l
(1/10) https://econ.st/36v2q3l
Britain's regulator was able to make a decision quickly thanks to rolling reviews of vaccine-trial data. This means results were scrutinised as they became available (2/10) https://econ.st/3o9mM82
It is the first time that an mRNA vaccine has been authorised for human use. Our briefing from November explains how the Pfizer-BioNTech jab works (3/10) https://econ.st/33wc6bR
America will soon consider the Pfizer vaccine for use. Another vaccine from Moderna is likely to be the next to be given permission for wider use. Moderna reported 95% efficacy. (4/10) https://econ.st/36v2Art
The AstraZeneca-Oxford vaccine will follow next. It is cheap and can be kept for at least six months in a normal fridge. The Pfizer jab needs ultra-cold storage of -70°C, and can be kept in a fridge for a week; Moderna's can stay in a fridge for a month (5) https://econ.st/3luTxuE
There is capacity to make 3bn doses of the AstraZeneca-Oxford vaccine over the course of 2021. Pfizer-BioNTech have estimated they could make 1.3bn and Moderna between 500m to 1bn doses (6/10) https://econ.st/3ohdfvS
So how should covid-19 vaccines be distributed? Rich countries have already snapped up more than half of Pfizer-BioNTech's projected supply (7/10) https://econ.st/3g2RVan
Where does this leave poorer countries? More than 180 countries have signed up to the COVAX initiative which allows rich countries to subsidise vaccines for poorer ones (8/10) https://econ.st/3lzSCch
But how can governments convince people to get vaccinated? Writing for The Economist, @katy_milkman explains why behavioural science offers the key (9/10) https://econ.st/2JzvQEf
And finally, keep up to date with coronavirus news as it unfolds, by heading to our covid-19 hub (10/10) https://econ.st/3fXSu5n
